Mark Tidswell to Morpholines
This is a "connection" page, showing publications Mark Tidswell has written about Morpholines.
Connection Strength
0.272
-
Collins SP, Shotwell MS, Strich JR, Gibbs KW, de Wit M, Files DC, Harkins M, Hudock K, Merck LH, Moskowitz A, Apodaca KD, Barksdale A, Safdar B, Javaheri A, Sturek JM, Schrager H, Iovine NM, Tiffany B, Douglas I, Levitt J, Ginde AA, Hager DN, Shapiro N, Duggal A, Khan A, Lanspa M, Chen P, Gentile N, Harris E, Gong M, Sellers S, Goodwin AJ, Tidswell MA, Filbin M, Desai N, Guti?rrez F, Estrada V, Burgos J, Boyles T, Pa?o-Pardo JR, Hussen N, Rosenberg Y, Troendle J, Bernard GR, Bistran-Hall AJ, Walsh K, Casey JD, DeClercq J, Joly MM, Pulley J, Rice TW, Schildcrout JS, Wang L, Semler MW, Self WH. Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia: A Randomized Clinical Trial. JAMA Netw Open. 2024 12 02; 7(12):e2448215.
Score: 0.213
-
Da Cruz RS, Teague HL, Ramos-Benitez MJ, Malavez-Cajigas SJ, Williams T, Miao R, Tian X, Lin G, Busse LW, Khan A, Moskowitz A, Hager DN, Rice TW, Ginde AA, Iovine NM, Chen P, Safdar B, Gibbs KW, Javaheri A, de Wit M, Harkins M, Hudock K, Merck LH, Barksdale A, Sturek JM, Schrager H, Shapiro NI, Lanspa M, Harris E, Sellers S, Goodwin AJ, Tidswell MA, Filbin MR, Shotwell MS, Semler MW, Self WH, Collins SP, Strich JR. Impact of Fostamatinib on Inflammatory Biomarkers in Hospitalized Patients With COVID-19. Crit Care Explor. 2026 Jul 01; 8(7):e1405.
Score: 0.059